Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 13:14:1229674.
doi: 10.3389/fimmu.2023.1229674. eCollection 2023.

Rare solid tumors in a patient with Wiskott-Aldrich syndrome after hematopoietic stem cell transplantation: case report and review of literature

Affiliations
Review

Rare solid tumors in a patient with Wiskott-Aldrich syndrome after hematopoietic stem cell transplantation: case report and review of literature

Emma Coppola et al. Front Immunol. .

Abstract

Background and aims: Wiskott-Aldrich syndrome (WAS) is an X-linked recessive primary immunodeficiency disorder characterized by severe eczema, recurrent infections, and micro-thrombocytopenia. Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative therapeutic option for patients with classic form. The risk of developing post-transplant tumors appears to be higher in patients with WAS than in other inborn errors of immunity (IEIs), but the actual incidence is not well defined, due to the scarcity of published data.

Methods: Herein, we describe a 10-year-old patient diagnosed with WAS, treated with HSCT in the first year of life, who subsequently developed two rare solid tumors, kaposiform hemangioendothelioma and desmoid tumor. A review of the literature on post-HSCT tumors in WAS patients has been performed.

Results: The patient received diagnosis of classic WAS at the age of 2 months (Zhu score = 3), confirmed by WAS gene sequencing, which detected the nonsense hemizygous c.37C>T (Arg13X) mutation. At 9 months, patient underwent HSCT from a matched unrelated donor with an adequate immune reconstitution, characterized by normal lymphocyte subpopulations and mitogen proliferation tests. Platelet count significantly increased, even though platelet count never reached reference values. A mixed chimerism was also detected, with a residual WASP- population on monocytes (27.3%). The patient developed a kaposiform hemangioendothelioma at the age of 5. A second abdominal tumor was identified, histologically classified as a desmoid tumor when he reached the age of 10 years. Both hematopoietic and solid tumors were identified in long-term WAS survivors after HSCT.

Conclusion: Here, we describe the case of a patient with WAS who developed two rare solid tumors after HSCT. An active surveillance program for the risk of tumors is necessary in the long-term follow-up of post-HSCT WAS patients.

Keywords: Wiskott Aldrich syndrome; case report; hemangioendothelioma kaposiform desmoid tumor; hematopoietic stem cell transplantation; inborn errors of immune system; malignancies.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
(A) Kaposiform emangioendothelioma: lobules of tumor cells coalesce and the capillaries form solid sheets with occasional slit-like lumens (H&E, ×100). (B) Kaposiform hemangioendothelioma: in some areas, the endothelial cells have a prominent spindled appearance (H&E, ×200). (C) Kaposiform hemangiothelioma: lumens filled with red blood cells (H&E, ×400). (D) Desmoid fibromatosis: spindled fibroblasts are arranged in bundles (H&E, ×400).
Figure 2
Figure 2
Abdominal CT performed at the diagnosis. The expansive mass is located in the left hypochondrium, inseparable from the contiguous walls of the colon and in close proximity to the lower pole of the spleen (A–F).
Figure 3
Figure 3
Timeline of major clinical events of the patient. HSCT, hematopoietic stem cells transplantation; WAS, Wiskott–Aldrich syndrome; mo, months; yrs, years.

References

    1. Ochs HD, Thrasher AJ. The wiskott-aldrich syndrome. J Allergy Clin Immunol (2006) 117:725–38; quiz 39. doi: 10.1016/j.jaci.2006.02.005 - DOI - PubMed
    1. Rivers E, Thrasher AJ. Wiskott-Aldrich syndrome protein: Emerging mechanisms in immunity. . Eur J Immunol (2017) 47:1857–66. doi: 10.1002/eji.201646715 - DOI - PMC - PubMed
    1. Castagnoli R, Delmonte OM, Calzoni E, Notarangelo LD. Hematopoietic stem cell transplantation in primary immunodeficiency diseases: Current status and future perspectives. Front Pediatr (2019) 7:295. doi: 10.3389/fped.2019.00295 - DOI - PMC - PubMed
    1. Gennery AR, Lankester A. Inborn errors working party of the European society for B,Marrow T. Long term outcome and immune function after hematopoietic stem cell transplantation for primary immunodeficiency. Front Pediatr (2019) 7:381. doi: 10.3389/fped.2019.00381 - DOI - PMC - PubMed
    1. Albert MH, Slatter MA, Gennery AR, Güngör T. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis. Blood (2022) 139:2066–79. doi: 10.1182/blood.2021014687 - DOI - PubMed

Supplementary concepts